PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.31%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.61%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
2.91%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 1.34%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
7.71%
EBIT growth of 7.71% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
7.71%
Operating income growth of 7.71% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
4.16%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 0.59%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
4.15%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 0.94%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
4.15%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 0.95%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.22%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.16%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.83%
10Y revenue/share CAGR 75-90% of Medical - Pharmaceuticals median of 42.67%. John Neff would seek operational improvements to catch up with peers.
51.99%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 11.74%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
23.42%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 13.72%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.42%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 15.61% over a decade. Joel Greenblatt might see a standout compounder of earnings.
33.73%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 4.12%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
23.99%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 1.60%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
167.66%
Equity/share CAGR of 167.66% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
110.15%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 22.31%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
52.73%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 5.23%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
77.78%
3Y dividend/share CAGR of 77.78% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
14.05%
Receivables growth far exceeding Medical - Pharmaceuticals median. Jim Chanos suspects potential red flags in revenue quality.
-0.11%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-0.78%
Assets shrink while Medical - Pharmaceuticals median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
2.01%
Positive BV/share change while Medical - Pharmaceuticals median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-7.70%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
1.88%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.